Liraglutide increases islet Ca<sup>2+</sup> oscillation frequency and insulin secretion by activating hyperpolarization-activated cyclic nucleotide-gated channels.
Diabetes Obes Metab · 2022
Last updated 2026-05-28In lab tests, the GLP-1 drug liraglutide increased the frequency of calcium signals in insulin-producing beta cells and boosted insulin release in both mouse and human islet samples. The effect depended partly on liraglutide activating specific channels (HCN channels) and was also seen in cells from animals fed a high-fat diet. Liraglutide also sped up calcium signals in a smaller group of delta cells, but this change required the presence of beta cells.
AI summary of the abstract below.
| Journal | Diabetes Obes Metab, 2022 |
|---|---|
| Citations | 16 |
| Relative citation ratio | 1.49 |
| NIH percentile | 64 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
AIM: To determine whether hyperpolarization-activated cyclic nucleotide-gated (HCN) channels impact glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) modulation of islet Ca handling and insulin secretion.
METHODS: The impact of liraglutide (GLP-1 analogue) on islet Ca handling, HCN currents and insulin secretion was monitored with fluorescence microscopy, electrophysiology and enzyme immunoassays, respectively. Furthermore, liraglutide-mediated β-to-δ-cell cross-communication was assessed following selective ablation of either mouse islet δ or β cells.
RESULTS: Liraglutide increased β-cell Ca oscillation frequency in mouse and human islets under stimulatory glucose conditions. This was dependent in part on liraglutide activation of HCN channels, which also enhanced insulin secretion. Similarly, liraglutide activation of HCN channels also increased β-cell Ca oscillation frequency in islets from rodents exposed to a diabetogenic diet. Interestingly, liraglutide accelerated Ca oscillations in a majority of islet δ cells, which showed synchronized Ca oscillations equivalent to β cells; therefore, we assessed if either cell type was driving this liraglutide-mediated islet Ca response. Although δ-cell loss did not impact liraglutide-mediated increase in β-cell Ca oscillation frequency, β-cell ablation attenuated liraglutide-facilitated acceleration of δ-cell Ca oscillations.
CONCLUSION: The data presented here show that liraglutide-induced stimulation of islet HCN channels augments Ca oscillation frequency. As insulin secretion oscillates with β-cell Ca , these findings have important implications for pulsatile insulin secretion that is probably enhanced by liraglutide activation of HCN channels and therapeutics that target GLP-1Rs for treating diabetes. Furthermore, these studies suggest that liraglutide as well as GLP-1-based therapies enhance δ-cell Ca oscillation frequency and somatostatin secretion kinetics in a β-cell-dependent manner.
Verbatim abstract via PubMed 35546791 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.